Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.
Although executed by different attackers – Axios by North Korean-linked goons, and Trivy et al. by a loosely knit band of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results